Current status of an implant-based augmentation mammaplasty in Korean women: Implications for risk management and social sustainability of breast implant industry in the context of the first Korean case of a medical device fraud.

Medicine 2025 Vol.104(36) p. e44092

Kim R

관련 도메인

Abstract

Stakeholders in the breast implant industry in Korea have recently experienced a crisis from breast implant-associated anaplastic large cell lymphoma and the first Korean case of a medical device fraud. We compared the short-term safety between the microtextured devices that are commercially available after the occurrence of breast implant crisis in Korea. The current study was conducted in a cohort of Korean women who had received an implant-based augmentation mammaplasty for aesthetic purposes between November 14, 2020 and October 13, 2022. We considered risk factors of complications in analyzing the safety of devices for the current study. A total of 801 Korean women (n = 801) were finally assessed. Incidences of capsular contracture were 1.79% (3/168), 3.64% (21/577), 8.11% (3/37), and 10.53% (2/19) in the patients receiving Motiva Ergonomix, Sebbin Sublimity, Sebbin Integrity, and Eurosilicone Round Collection, respectively. These differences reached statistical significance (P < .05). There were 2 women with rupture after receiving Sebbin Sublimity, although there were no cases of rupture in association with other brands of breast implants. Overall capsular contracture-free survival was estimated at 681.470 ± 8.314 (95% confidence interval [CI] 665.174-697.766) days. By breast implants, it was 708.899 ± 8.595 (95% CI 692.053-725.745), 599.327 ± 6.607 (95% CI 586.378-612.277), 584.941 ± 22.965 (95% CI 539.931-629.952), and 572.492 ± 37.374 (95% CI 499.240-645.745) days in the patients receiving Motiva Ergonomix, Sebbin Sublimity, Sebbin Integrity, and Eurosilicone Round Collection, respectively, in the increasing order. In conclusion, our results indicate that Motiva Ergonomix Round SilkSurface is currently a relatively safer device as compared with others in the context of the first Korean case of a medical device fraud. The breast implant industry in Korea should be aware of the importance of the social sustainability in manufacturing a device.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
해부 breast 유방 dict 7
시술 mammaplasty 유방성형술 dict 2
합병증 capsular contracture 피막구축 dict 2
합병증 anaplastic large cell lymphoma 보형물연관 역형성대세포림프종 dict 1
합병증 breast implant scispacy 1
합병증 capsular contracture-free scispacy 1
약물 801 C5395487
801
scispacy 1
약물 CI 586.378-612.277 scispacy 1
질환 breast implant C0178391
breast implant procedure
scispacy 1
질환 breast implant-associated anaplastic large cell lymphoma C4528210
Breast implant-associated anaplastic large-cell lymphoma
scispacy 1
질환 rupture C3203359
Rupture
scispacy 1
질환 584.941 scispacy 1
질환 breast implant industry scispacy 1
기타 implant-based scispacy 1
기타 women scispacy 1
기타 patients scispacy 1

MeSH Terms

Humans; Female; Breast Implants; Republic of Korea; Adult; Middle Aged; Risk Management; Breast Implantation; Mammaplasty; Fraud; Lymphoma, Large-Cell, Anaplastic; Risk Factors; Retrospective Studies; Implant Capsular Contracture

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문